CERVICAL ADENOSQUAMOUS CARCINOMA
Clinical trials for CERVICAL ADENOSQUAMOUS CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CERVICAL ADENOSQUAMOUS CARCINOMA trials appear
Sign up with your email to follow new studies for CERVICAL ADENOSQUAMOUS CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New smart chemo targets tumors, spares healthy tissue
Disease control Recruiting nowThis early-phase trial tests a new drug called AVA6103 in 174 people with advanced solid tumors (like pancreatic, stomach, or lung cancer) that have not responded to standard treatments. The drug is designed to activate only inside tumors, potentially killing cancer cells while r…
Matched conditions: CERVICAL ADENOSQUAMOUS CARCINOMA
Phase: PHASE1 • Sponsor: Avacta Life Sciences Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Could a 3-Week radiation course beat the standard for cervical cancer?
Disease control Recruiting nowThis study compares a shorter, higher-dose radiation schedule (hypofractionated radiotherapy) to the standard longer course for women with locally advanced cervical cancer in Uganda. About 278 participants will receive either the shorter or standard radiation, plus chemotherapy a…
Matched conditions: CERVICAL ADENOSQUAMOUS CARCINOMA
Phase: PHASE2 • Sponsor: Uganda Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Virus therapy takes on cervical and endometrial cancer
Disease control Recruiting nowThis study tests a modified virus (KD01) that targets and kills cancer cells, given alone or with an immunotherapy drug (AK104). It includes 97 women with cervical or endometrial cancer, some of whom have not responded to standard treatments. The goal is to see if the virus is sa…
Matched conditions: CERVICAL ADENOSQUAMOUS CARCINOMA
Phase: PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo aims to stop cervical cancer recurrence in high-risk patients
Disease control Recruiting nowThis study tests whether adding the drug serplulimab to standard chemoradiotherapy after surgery can help prevent cervical cancer from returning in patients with multiple risk factors. About 134 women aged 18-65 with PD-L1 positive cervical cancer will be randomly assigned to rec…
Matched conditions: CERVICAL ADENOSQUAMOUS CARCINOMA
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC